id,method,gold_answer,model_raw,model_answer,correct_em,f1,grounded,abstained,hallucinated,tokens_out,latency_ms
1,direct,yes,yes [ID:PubMedQA-26348845],yes,1,1.0,1,0,0,2,884
1,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes,yes,1,1.0,0,0,0,50,1129
2,direct,no,yes [ID:PubMedQA-10973547],yes,0,0.0,1,0,0,2,321
2,cot,no,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,0,0.0,0,0,0,38,927
3,direct,yes,yes [ID:PubMedQA-26163474],yes,1,1.0,1,0,0,2,320
3,cot,yes,Final Answer: yes | Reasoning: the passage states an association between sublingual varices and hypertension; the association is quantified with an odds ratio of 2.25; the association is also quantified with a positive predictive value of 0.5; the association is also quantified with a negative predictive value of 0.80; therefore the correct label is yes [ID:PubMedQA-26163474],yes,1,1.0,1,0,0,56,1620
4,direct,yes,yes [ID:PubMedQA-24374414],yes,1,1.0,1,0,0,2,320
4,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,930
5,direct,yes,Not in context.,not in context,0,0.0,0,1,0,3,102
5,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes [ID:PubMedQA-18507507],yes,1,1.0,1,0,0,51,1380
6,direct,yes,Not in context.,not in context,0,0.0,0,1,0,3,97
6,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes [ID:PubMedQA-23495128],yes,1,1.0,1,0,0,51,1384
7,direct,no,no [ID:PubMedQA-17192736],no,1,1.0,1,0,0,2,321
7,cot,no,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,0,0.0,0,0,0,38,931
8,direct,yes,yes [ID:PubMedQA-12163782],yes,1,1.0,1,0,0,2,323
8,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes [ID:PubMedQA-12163782],yes,1,1.0,1,0,0,51,1391
9,direct,yes,no [ID:PubMedQA-9582182],no,0,0.0,1,0,0,2,296
9,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes,yes,1,1.0,0,0,0,50,1119
10,direct,yes,yes [ID:PubMedQA-25588461],yes,1,1.0,1,0,0,2,312
10,cot,yes,"Final Answer: yes | Reasoning: the passage states that a-tDCS was able to boost cortical connectivity and excitability in all HC, MCS, and to unmask such excitability/connectivity in some UWS patients; the absence of such effect in UWS patients in comparison to HC and MCS patients is consistent with the absence of conscious behavior in UWS; therefore the correct label is yes [ID:PubMedQA-25588461]",yes,1,1.0,1,0,0,63,1688
11,direct,yes,no [ID:PubMedQA-23453079],no,0,0.0,1,0,0,2,313
11,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is highlighted; language is affirmative rather than uncertain; therefore the correct label is yes [ID:PubMedQA-23453079],yes,1,1.0,1,0,0,51,1385
12,direct,yes,Not in context.,not in context,0,0.0,0,1,0,3,101
12,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,917
13,direct,yes,yes [ID:PubMedQA-21084567].,yes,1,1.0,1,0,0,2,308
13,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes,yes,1,1.0,0,0,0,50,1116
14,direct,yes,yes [ID:PubMedQA-11601252],yes,1,1.0,1,0,0,2,318
14,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,918
15,direct,yes,yes [ID:PubMedQA-20577124].,yes,1,1.0,1,0,0,2,319
15,cot,yes,Final Answer: yes | Reasoning: the passage states leptin induced NADPH oxidase activation; leptin is a pro-inflammatory cytokine; NADPH oxidase is a pro-inflammatory enzyme; obesity is a pro-inflammatory condition; therefore the correct label is yes [ID:PubMedQA-20577124],yes,1,1.0,1,0,0,36,1510
16,direct,no,no [ID:PubMedQA-16647887].,no,1,1.0,1,0,0,2,312
16,cot,no,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,0,0.0,0,0,0,38,915
17,direct,yes,not in context.,not in context,0,0.0,0,1,0,3,108
17,cot,yes,Final Answer: no | Reasoning: the passage states that blood pressure and low back pain are inversely related; the inverse relationship is not causal; therefore the correct label is no [ID:PubMedQA-24019262],no,0,0.0,1,0,0,31,925
18,direct,yes,maybe [ID:PubMedQA-18670651].,maybe,0,0.0,1,0,0,2,320
18,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,924
19,direct,no,yes [ID:PubMedQA-15137012],yes,0,0.0,1,0,0,2,312
19,cot,no,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,0,0.0,0,0,0,38,918
20,direct,yes,yes [ID:PubMedQA-11380492].,yes,1,1.0,1,0,0,2,337
20,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes [ID:PubMedQA-11380492],yes,1,1.0,1,0,0,51,1393
21,direct,no,no [ID:PubMedQA-17274051],no,1,1.0,1,0,0,2,319
21,cot,no,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,0,0.0,0,0,0,38,925
22,direct,yes,yes [ID:PubMedQA-12846929].,yes,1,1.0,1,0,0,2,311
22,cot,yes,"Final Answer: yes | Reasoning: The passage states that lower socioeconomic status patients had more health problems, less functioning, and more symptoms than affluent patients. This is a clear difference in quality of life. The difference is not explained by the fact that lower socioeconomic status patients are more likely to die, because the study is controlled for time. Therefore, the correct label is yes.",yes,1,1.0,0,0,0,65,1365
23,direct,yes,yes [ID:PubMedQA-18948835],yes,1,1.0,1,0,0,2,311
23,cot,yes,Final Answer: yes | Reasoning: the passage states neuromedin u reduces insulin secretion; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes,yes,1,1.0,0,0,0,51,1167
24,direct,no,yes [ID:PubMedQA-23052500],yes,0,0.0,1,0,0,2,319
24,cot,no,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,0,0.0,0,0,0,38,923
25,direct,no,yes [ID:PubMedQA-25488308],yes,0,0.0,1,0,0,2,319
25,cot,no,Final Answer: yes | Reasoning: the passage states bone thickness and inter-radicular space affect miniscrew placement; the study is about mandible; the study is about posterior mandible; therefore the correct label is yes [ID:PubMedQA-25488308],yes,0,0.0,1,0,0,34,1061
26,direct,maybe,no [ID:PubMedQA-24946973],no,0,0.0,1,0,0,2,318
26,cot,maybe,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,0,0.0,0,0,0,38,924
27,direct,yes,yes [ID:PubMedQA-27456836],yes,1,1.0,1,0,0,2,319
27,cot,yes,Final Answer: yes | Reasoning: the passage states that ECL assays improve prediction of time to type 1 diabetes in autoantibody-positive TrialNet subjects; the context does not contradict this statement; therefore the correct label is yes [ID:PubMedQA-27456836],yes,1,1.0,1,0,0,37,1154
28,direct,yes,yes [ID:PubMedQA-17244100],yes,1,1.0,1,0,0,2,311
28,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,917
29,direct,yes,yes [ID:PubMedQA-23347337],yes,1,1.0,1,0,0,2,318
29,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes,yes,1,1.0,0,0,0,50,1120
30,direct,yes,yes [ID:PubMedQA-24098953].,yes,1,1.0,1,0,0,2,310
30,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,915
31,direct,no,Not in context.,not in context,0,0.0,0,1,0,3,106
31,cot,no,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is highlighted; language is affirmative rather than uncertain; therefore the correct label is yes,yes,0,0.0,0,0,0,50,1120
32,direct,yes,yes [ID:PubMedQA-12913878].,yes,1,1.0,1,0,0,2,311
32,cot,yes,Final Answer: yes | Reasoning: the passage states LITT induces an opening of the BBB; the BBB is disrupted locoregionally; the BBB is disrupted for paclitaxel; paclitaxel is a chemotherapeutic agent; therefore the correct label is yes [ID:PubMedQA-12913878],yes,1,1.0,1,0,0,38,1322
33,direct,yes,maybe [ID:PubMedQA-16097998].,maybe,0,0.0,1,0,0,2,306
33,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,912
34,direct,no,no [ID:PubMedQA-10593212],no,1,1.0,1,0,0,2,312
34,cot,no,"Final Answer: yes | Reasoning: the passage states that no significant differences were found between the LOC, no LOC, or uncertain LOC groups for any of the neuropsychological measures used; the absence of clear lack of benefit means not no; therefore the correct label is yes [ID:PubMedQA-10593212]",yes,0,0.0,1,0,0,47,1232
35,direct,yes,yes [ID:PubMedQA-22012962].,yes,1,1.0,1,0,0,2,317
35,cot,yes,Final Answer: yes | Reasoning: the passage states that divorced and single men have higher mortality than widowed men; the passage also states that divorced and single women have higher mortality than widowed women; therefore the correct label is yes,yes,1,1.0,0,0,0,40,858
36,direct,yes,yes [ID:PubMedQA-8910148],yes,1,1.0,1,0,0,2,302
36,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,921
37,direct,no,no [ID:PubMedQA-20337874].,no,1,1.0,1,0,0,2,309
37,cot,no,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,0,0.0,0,0,0,38,913
38,direct,no,Not in context.,not in context,0,0.0,0,1,0,3,99
38,cot,no,Final Answer: yes | Reasoning: the passage states women have higher rates of depression; no gender difference in depression symptoms is reported; therefore the correct label is yes [ID:PubMedQA-15052394],yes,0,0.0,1,0,0,29,839
39,direct,no,maybe [ID:PubMedQA-18439500],maybe,0,0.0,1,0,0,2,333
39,cot,no,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes [ID:PubMedQA-18439500],yes,0,0.0,1,0,0,51,1381
40,direct,yes,yes [ID:PubMedQA-27491658],yes,1,1.0,1,0,0,2,302
40,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is highlighted; language is affirmative rather than uncertain; therefore the correct label is yes,yes,1,1.0,0,0,0,50,1093
41,direct,no,yes [ID:PubMedQA-16962519],yes,0,0.0,1,0,0,2,316
41,cot,no,Final Answer: yes | Reasoning: the passage states uterine myomas volume decreased in the first to second period and increased in the second to third period; the confidence intervals for the percentages are narrow; the confidence intervals for the volume changes are narrow; the confidence intervals for the volume changes are consistent across the three periods; therefore the correct label is yes [ID:PubMedQA-16962519],yes,0,0.0,1,0,0,63,1463
42,direct,yes,yes [ID:PubMedQA-9199905],yes,1,1.0,1,0,0,2,302
42,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,910
43,direct,yes,no [ID:PubMedQA-14745753].,no,0,0.0,1,0,0,2,309
43,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes,yes,1,1.0,0,0,0,50,1101
44,direct,yes,yes [ID:PubMedQA-23506394].,yes,1,1.0,1,0,0,2,309
44,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is highlighted; language is affirmative rather than uncertain; therefore the correct label is yes [ID:PubMedQA-23506394],yes,1,1.0,1,0,0,51,1363
45,direct,yes,yes [ID:PubMedQA-20064872],yes,1,1.0,1,0,0,2,317
45,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes [ID:PubMedQA-20064872],yes,1,1.0,1,0,0,51,1380
46,direct,yes,yes [ID:PubMedQA-22683044],yes,1,1.0,1,0,0,2,317
46,cot,yes,Final Answer: yes | Reasoning: the passage states that open access articles are more often cited than non-open access articles; the study is about intensive care medicine; the study is about open access; therefore the correct label is yes [ID:PubMedQA-22683044],yes,1,1.0,1,0,0,40,1066
47,direct,yes,yes [ID:PubMedQA-23870157].,yes,1,1.0,1,0,0,2,316
47,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is highlighted; language is affirmative rather than uncertain; therefore the correct label is yes [ID:PubMedQA-23870157],yes,1,1.0,1,0,0,51,1374
48,direct,yes,not in context,not in context,0,0.0,0,1,0,3,84
48,cot,yes,Final Answer: yes | Reasoning: the passage states ultrasound is not established for the diagnosis of fractures; the aim of the study is to compare ultrasound and X-ray; the study reports ultrasound and X-ray findings; the study reports ultrasound and X-ray findings; therefore the correct label is yes [ID:PubMedQA-20401819],yes,1,1.0,1,0,0,49,1398
49,direct,yes,yes [ID:PubMedQA-22117569].,yes,1,1.0,1,0,0,2,312
49,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes [ID:PubMedQA-22117569],yes,1,1.0,1,0,0,51,1367
50,direct,yes,yes [ID:PubMedQA-10811329],yes,1,1.0,1,0,0,2,316
50,cot,yes,"Final Answer: yes | Reasoning: the passage states 99mTc-WBC scintigraphy and UGI-SBFT were used to exclude IBD; the study design is a retrospective study; the study population is children suspected of having IBD; the study results are 99mTc-WBC scintigraphy was positive in all but three newly diagnosed Crohn's disease, ulcerative colitis, or miscellaneous colitis children; UGI-SBFT studies were normal in 81% of children with a true-positive 99mTc-WBC scan; therefore the correct label is yes [ID:PubMedQA-10811329]",yes,1,1.0,1,0,0,75,2520
51,direct,yes,no [ID:PubMedQA-23224030],no,0,0.0,1,0,0,2,316
51,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,915
52,direct,yes,yes [ID:PubMedQA-24318956],yes,1,1.0,1,0,0,2,309
52,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is highlighted; language is affirmative rather than uncertain; therefore the correct label is yes,yes,1,1.0,0,0,0,50,1112
53,direct,yes,yes [ID:PubMedQA-24014276],yes,1,1.0,1,0,0,2,317
53,cot,yes,Final Answer: yes | Reasoning: optimism is mentioned as a predictor of survival in the context of the oldest-old; optimism is defined as a positive outlook on future; the study found that optimistic women and men were at lower risk of death compared to their neutral counterparts; the study controlled for confounding factors such as baseline physical and cognitive functioning and disease; therefore the correct label is yes,yes,1,1.0,0,0,0,68,1373
54,direct,yes,yes [ID:PubMedQA-26561905],yes,1,1.0,1,0,0,2,307
54,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,912
55,direct,yes,yes [ID:PubMedQA-23806388],yes,1,1.0,1,0,0,2,315
55,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is highlighted; language is affirmative rather than uncertain; therefore the correct label is yes,yes,1,1.0,0,0,0,50,1111
56,direct,no,maybe [ID:PubMedQA-7482275],maybe,0,0.0,1,0,0,2,295
56,cot,no,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,0,0.0,0,0,0,38,915
57,direct,yes,yes [ID:PubMedQA-23072266],yes,1,1.0,1,0,0,2,317
57,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is highlighted; language is affirmative rather than uncertain; therefore the correct label is yes,yes,1,1.0,0,0,0,50,1114
58,direct,yes,yes [ID:PubMedQA-25432938].,yes,1,1.0,1,0,0,2,304
58,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes,yes,1,1.0,0,0,0,50,1104
59,direct,no,no [ID:PubMedQA-26485091].,no,1,1.0,1,0,0,2,309
59,cot,no,Final Answer: no | Reasoning: the passage states that AAPs resulted in higher mean adjusted pharmacy costs and higher mean adjusted total mental health-related costs; the passage does not state that AAPs resulted in cost savings; therefore the correct label is no,no,1,1.0,0,0,0,42,893
60,direct,yes,yes [ID:PubMedQA-15208005],yes,1,1.0,1,0,0,2,305
60,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is highlighted; language is affirmative rather than uncertain; therefore the correct label is yes,yes,1,1.0,0,0,0,50,1110
61,direct,yes,yes [ID:PubMedQA-10759659],yes,1,1.0,1,0,0,2,305
61,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is highlighted; language is affirmative rather than uncertain; therefore the correct label is yes [ID:PubMedQA-10759659],yes,1,1.0,1,0,0,51,1347
62,direct,maybe,no [ID:PubMedQA-25277731].,no,0,0.0,1,0,0,2,301
62,cot,maybe,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is highlighted; language is affirmative rather than uncertain; therefore the correct label is yes,yes,0,0.0,0,0,0,50,1094
63,direct,yes,maybe [ID:PubMedQA-26818046],maybe,0,0.0,1,0,0,2,316
63,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes,yes,1,1.0,0,0,0,50,1108
64,direct,yes,yes [ID:PubMedQA-15065192],yes,1,1.0,1,0,0,2,310
64,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,909
65,direct,yes,Not in context.,not in context,0,0.0,0,1,0,3,98
65,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,917
66,direct,no,yes [ID:PubMedQA-17462393],yes,0,0.0,1,0,0,2,316
66,cot,no,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is highlighted; language is affirmative rather than uncertain; therefore the correct label is yes,yes,0,0.0,0,0,0,50,1114
67,direct,no,no [ID:PubMedQA-22504515].,no,1,1.0,1,0,0,2,315
67,cot,no,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes,yes,0,0.0,0,0,0,50,1107
68,direct,yes,yes [ID:PubMedQA-25675614].,yes,1,1.0,1,0,0,2,308
68,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,907
69,direct,maybe,no [ID:PubMedQA-18235194],no,0,0.0,1,0,0,2,300
69,cot,maybe,"Final Answer: yes | Reasoning: the passage states that the specialized training program was more effective than the control in reading abilities; the effect was only found in children with a history of hearing loss, actual hearing loss or pathologic middle ear findings; therefore the correct label is yes [ID:PubMedQA-18235194]",yes,0,0.0,1,0,0,50,1178
70,direct,yes,not in context.,not in context,0,0.0,0,1,0,3,98
70,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes,yes,1,1.0,0,0,0,50,1113
71,direct,no,yes [ID:PubMedQA-21823940],yes,0,0.0,1,0,0,2,309
71,cot,no,Final Answer: yes | Reasoning: the passage states that the MTO records and self-reports agree on collisions; kappa coefficient for collision correlation was in the moderate range of agreement; therefore the correct label is yes [ID:PubMedQA-21823940],yes,0,0.0,1,0,0,36,1030
72,direct,yes,yes [ID:PubMedQA-10331115],yes,1,1.0,1,0,0,2,309
72,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes,yes,1,1.0,0,0,0,50,1104
73,direct,no,maybe [ID:PubMedQA-24684514],maybe,0,0.0,1,0,0,2,316
73,cot,no,"Final Answer: no | Reasoning: the passage states that the procedure is expensive, requires close monitoring and is often inconvenient for patients with reduced mobility; the passage also states that the procedure is not effective for all patients; therefore the correct label is no",no,1,1.0,0,0,0,44,863
74,direct,yes,yes [ID:PubMedQA-14968373].,yes,1,1.0,1,0,0,2,309
74,cot,yes,Final Answer: yes | Reasoning: the passage states that air-encephalography is the gold standard for differentiating communicating and non-communicating hydrocephalus; the study found that the only CT finding that correlated with the type of hydrocephalus was the shape of the third ventricle; significantly more children with non-communicating hydrocephalus had a rounded third ventricle than those with communicating hydrocephalus; therefore the correct label is yes [ID:PubMedQA-14968373],yes,1,1.0,1,0,0,65,1975
75,direct,no,yes [ID:PubMedQA-20187289],yes,0,0.0,1,0,0,2,309
75,cot,no,"Final Answer: yes | Reasoning: the passage states that prescriptions were used as a proxy for asthma; the authors replicated the selection procedure of Stock et al. using data on 290,919 children aged 0-17 years insured in the GmÃ¼nder ErsatzKasse (GEK) in 2005; asthma prevalence was also estimated in a sample of 17,641 children aged 0-17 years participating in the German Health Interview and Examination Survey for Children and Adolescents (KiGGS) from 2003 to 2006; the authors found that asthma prevalence in children aged 0-4 years insured in the GEK ranged from 11.7 to 17.7% for boys and from 7.2 to 11.1% for girls; a steady decline in prevalence was observed in older age groups; asthma prevalence estimated in the KiGGS data showed a quite different distribution; in the age group 0-4 years, prevalences were found to range from 0 to 2.6% in boys and from 0 to 1.0% in girls; in children>4 years, prevalences were found to increase with increasing age; the authors concluded that prescriptions are a good proxy for asthma in children [ID:PubMedQA-20187289]",yes,0,0.0,1,0,0,176,4943
76,direct,no,no [ID:PubMedQA-22972546],no,1,1.0,1,0,0,2,309
76,cot,no,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,0,0.0,0,0,0,38,908
77,direct,no,not in context,not in context,0,0.0,0,1,0,3,83
77,cot,no,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,0,0.0,0,0,0,38,913
78,direct,no,yes [ID:PubMedQA-15703931],yes,0,0.0,1,0,0,2,317
78,cot,no,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings are highlighted in the passage.,yes,0,0.0,0,0,0,38,919
79,direct,yes,yes [ID:PubMedQA-12913347].,yes,1,1.0,1,0,0,2,316
79,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,913
80,direct,yes,yes [ID:PubMedQA-9550200],yes,1,1.0,1,0,0,2,285
80,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,891
81,direct,yes,yes [ID:PubMedQA-26701174].,yes,1,1.0,1,0,0,2,316
81,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,916
82,direct,no,no [ID:PubMedQA-22186742].,no,1,1.0,1,0,0,2,304
82,cot,no,Final Answer: no | Reasoning: the passage describes a study that found no significant differences in patients' characteristics or survival between those with or without colonoscopy; the absence of significant differences in survival means that colonoscopy does not affect the management of acute diverticulitis; therefore the correct label is no [ID:PubMedQA-22186742],no,1,1.0,1,0,0,51,1314
83,direct,yes,yes [ID:PubMedQA-22532370],yes,1,1.0,1,0,0,2,308
83,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is highlighted; language is affirmative rather than uncertain; therefore the correct label is yes,yes,1,1.0,0,0,0,50,1101
84,direct,yes,yes [ID:PubMedQA-22188074].,yes,1,1.0,1,0,0,2,315
84,cot,yes,Final Answer: yes | Reasoning: the passage states that IADLs can help predict dementia at 1- and 2-year follow-up; the chi-square test shows a significant difference in conversion rate between participants with and without IADL disabilities; the structural equation model confirms that IADL disability can help predict dementia; therefore the correct label is yes [ID:PubMedQA-22188074],yes,1,1.0,1,0,0,55,1602
85,direct,yes,yes [ID:PubMedQA-19653482],yes,1,1.0,1,0,0,2,302
85,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is highlighted; language is affirmative rather than uncertain; therefore the correct label is yes,yes,1,1.0,0,0,0,50,1089
86,direct,yes,yes [ID:PubMedQA-18041059],yes,1,1.0,1,0,0,2,315
86,cot,yes,Final Answer: yes | Reasoning: the passage states that the risk of cardiovascular events was significantly higher in the tamoxifen arm; the comparator was aromatase inhibitors; no contradictory findings were highlighted in the passage; therefore the correct label is yes [ID:PubMedQA-18041059],yes,1,1.0,1,0,0,41,1204
87,direct,yes,yes [ID:PubMedQA-21550158],yes,1,1.0,1,0,0,2,316
87,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,912
88,direct,no,yes [ID:PubMedQA-21849531],yes,0,0.0,1,0,0,2,309
88,cot,no,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,0,0.0,0,0,0,38,909
89,direct,yes,yes [ID:PubMedQA-10430303].,yes,1,1.0,1,0,0,2,309
89,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,905
90,direct,maybe,yes [ID:PubMedQA-24336869],yes,0,0.0,1,0,0,2,315
90,cot,maybe,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes,yes,0,0.0,0,0,0,50,1107
91,direct,no,Not in context.,not in context,0,0.0,0,1,0,3,105
91,cot,no,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes,yes,0,0.0,0,0,0,50,1106
92,direct,yes,no [ID:PubMedQA-10411439].,no,0,0.0,1,0,0,2,309
92,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,907
93,direct,yes,Not in context.,not in context,0,0.0,0,1,0,3,105
93,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,916
94,direct,yes,yes [ID:PubMedQA-18179827],yes,1,1.0,1,0,0,2,309
94,cot,yes,Final Answer: yes | Reasoning: the passage states that topical ropivacaine reduced post-tonsillectomy morbidity; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes [ID:PubMedQA-18179827],yes,1,1.0,1,0,0,53,1544
95,direct,no,not in context.,not in context,0,0.0,0,1,0,3,105
95,cot,no,Final Answer: no | Reasoning: the passage states BD on admission had no statistically significant difference in means of BD between survivors and non survivors; therefore the correct label is no [ID:PubMedQA-26079501],no,1,1.0,1,0,0,32,913
96,direct,yes,yes [ID:PubMedQA-18388848],yes,1,1.0,1,0,0,2,305
96,cot,yes,Final Answer: yes | Reasoning: the passage states that children with a regular clinician had higher interpersonal quality; content of anticipatory guidance was slightly greater for children with a regular clinician; the passage does not mention any lack of benefit; therefore the correct label is yes,yes,1,1.0,0,0,0,46,922
97,direct,no,yes [ID:PubMedQA-24625433],yes,0,0.0,1,0,0,2,315
97,cot,no,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no evidence of harm offsetting benefit is given; language is affirmative rather than uncertain; therefore the correct label is yes,yes,0,0.0,0,0,0,50,1109
98,direct,yes,yes [ID:PubMedQA-27592038],yes,1,1.0,1,0,0,2,316
98,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,913
99,direct,yes,yes [ID:PubMedQA-22453060],yes,1,1.0,1,0,0,2,316
99,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,912
100,direct,yes,yes [ID:PubMedQA-24671913].,yes,1,1.0,1,0,0,2,316
100,cot,yes,Final Answer: yes | Reasoning: the passage states aspirin reduced recurrent MI; effect described as reduction not neutrality; result observed across subgroups implying robustness; comparator suggests improvement over standard care; no contradictory findings were highlighted in the passage.,yes,1,1.0,0,0,0,38,916
101,direct,not in context,Not in context. [ID:Decoy-1],not in context,1,1.0,1,1,0,4,220
101,cot,not in context,Context (ID:Demo-1): A randomized trial reported aspirin reduced the risk of recurrent myocardial infarction; benefits were consistent across subgroups; comparator was usual care; no contradictory findings were highlighted in the passage.,no,0,0.0,0,0,1,31,856
102,direct,not in context,Not in context. [ID:Decoy-2],not in context,1,1.0,1,1,0,4,202
102,cot,not in context,Context (ID:Demo-1): A randomized trial reported aspirin reduced the risk of recurrent myocardial infarction; benefits were consistent across subgroups; comparator was usual care; no contradictory findings were highlighted in the passage.,no,0,0.0,0,0,1,31,856
103,direct,not in context,Not in context. [ID:Decoy-3],not in context,1,1.0,1,1,0,4,202
103,cot,not in context,Context (ID:Demo-1):,not in context,1,1.0,0,1,0,2,180
104,direct,not in context,Not in context. [ID:Decoy-4],not in context,1,1.0,1,1,0,4,202
104,cot,not in context,Context (ID:Demo-1): A randomized trial reported aspirin reduced the risk of recurrent myocardial infarction; benefits were consistent across subgroups; comparator was usual care; no contradictory findings were highlighted in the passage.,no,0,0.0,0,0,1,31,856
105,direct,not in context,Not in context. [ID:Decoy-5],not in context,1,1.0,1,1,0,4,202
105,cot,not in context,Context (ID:Demo-1): A randomized trial reported aspirin reduced the risk of recurrent myocardial infarction; benefits were consistent across subgroups; comparator was usual care; no contradictory findings were highlighted in the passage.,no,0,0.0,0,0,1,31,856
106,direct,not in context,Not in context. [ID:Decoy-6],not in context,1,1.0,1,1,0,4,202
106,cot,not in context,Context (ID: Demo-1):,not in context,1,1.0,0,1,0,3,180
107,direct,not in context,Not in context. [ID:Decoy-7],not in context,1,1.0,1,1,0,4,202
107,cot,not in context,Context (ID:Demo-1): A randomized trial reported aspirin reduced the risk of recurrent myocardial infarction; benefits were consistent across subgroups; comparator was usual care; no contradictory findings were highlighted in the passage.,no,0,0.0,0,0,1,31,856
108,direct,not in context,Not in context. [ID:Decoy-8],not in context,1,1.0,1,1,0,4,202
108,cot,not in context,Context (ID:Demo-1):,not in context,1,1.0,0,1,0,2,180
109,direct,not in context,Not in context. [ID:Decoy-9],not in context,1,1.0,1,1,0,4,202
109,cot,not in context,Context (ID:Demo-1): A randomized trial reported aspirin reduced the risk of recurrent myocardial infarction; benefits were consistent across subgroups; comparator was usual care; no contradictory findings were highlighted in the passage.,no,0,0.0,0,0,1,31,856
110,direct,not in context,Not in context. [ID:Decoy-10],not in context,1,1.0,1,1,0,4,217
110,cot,not in context,Context (ID:Demo-1): A randomized trial reported aspirin reduced the risk of recurrent myocardial infarction; benefits were consistent across subgroups; comparator was usual care; no contradictory findings were highlighted in the passage.,no,0,0.0,0,0,1,31,856
